Institut Paoli-Calmettes (IPC) has acquired LASERGYN
Thanks to financial support from the ORTEC Group,
Institut Paoli-Calmettes (IPC) has acquired LASERGYN,
an innovative equipment for the management of post-treatment sequelae in cancer patients.
Marseille, May 26, 2023.
LASERGYN is an innovative equipment used at Institut Paoli-Calmettes in the care of female cancer patients to reduce the post-treatment sequelae and improve patients’ quality of life. The ORTEC Group provided financial support for the acquisition of this device and on May 25, a dedication plaque has been unveiled in the presence of Dr. Norbert VEY, the General Director of the IPC, and Mr. André EINAUDI, the President and CEO of the ORTEC Group.
LASERGYN is a CO2 laser device designed to treat urogenital changes in patients who have undergone chemotherapy, hormone therapy (breast cancer), or radiation therapy (perineal cancer). These treatments have a significant impact on patients’ quality of life.
Until now, the Institute’s practitioners referred patients to local physicians able to offer treatment, but the number of available doctors was insufficient to meet the growing demand.
Institut Paoli-Calmettes is now in a position to offer its patients a therapeutic solution using this innovative equipment.
“ As a referral center, we believe it is crucial for us to ensure comprehensive care by addressing the sequelae of our treatments and to support patients right through to the end of their treatment”, emphasized Dr. Camille JAUFFRET, a surgeon specializing in senology and gynecological oncology.
Thanks to the financial support from ORTEC, an engineering and construction services group committed to the long-term fight against cancer, IPC has been able to acquire this pioneering equipment.
About the Ortec Group
As an integrator of engineering and construction solutions, the ORTEC Group supports its clients in the design, implementation, and maintenance of their projects. Its range of services includes over 50 complementary areas of expertise deployed across various markets: energy, mining, pharmaceuticals, chemicals, defense, railway, food-processing, automotive, aeronautics, aerospace and local authorities.
The ORTEC Group operates in 25 countries on 4 continents, employs 14,000 people, and has achieved a turnover of 1.3 billion euros in 2022.
For more information: www.ortec-group.com/en
Media contact for the Ortec Group
Floriane LASSALLE-MASSIP : +33 6 77 70 26 48 | floriane.lassallemassip@ortec.fr
Follow Ortec: 
About IPC
Accredited with the highest level of certification for High Quality of Care by the French High Authority of Health (HAS) in 2021, and accredited as a Comprehensive Cancer Center by the Organization of European Cancer Institutes (OECI) in June 2019, Institut Paoli-Calmettes is a member of the Unicancer network. IPC brings together 1,900 medical and non-medical personnel committed to comprehensive management of all cancer-related pathologies through research, medical and supportive care, teaching and training. In 2022, IPC provided over 100,000 medical consultations and received nearly 12,000 new patients. Treatment at IPC is provided exclusively on the basis of social security rates, and no additional fees are charged at the facility. IPC has established cooperation with around twenty healthcare establishments in the region.
For more information: www.institutpaolicalmettes.fr
IPC press contact
Elisabeth BELARBI : +33 6 46 14 30 75 | belarbie@ipc.unicancer.fr
Follow the IPC:
